FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 
EBMT Center Identification Code (CIC):    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type: (check all that apply) 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type: (check all that apply) 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

Visit:

  
 nmlkji

100 day  
 nmlkji

6 months  
 nmlkji

1 year  
 nmlkji

2 years  
 nmlkji

> 2 years,  

 
 
Specify:    

 
 
1  Date of actual contact with the recipient to determine medical status for this follow-up report: __ __ __ __ - __ __- __ __  

 

Disease Relapses or Progression of Disability Post-HSCT 
 

2  Were there any relapses of multiple sclerosis (MS) since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  

 
 
3  Specify the date of first relapse since the date of the last report: __ __ __ __ - __ __- __ __  

  
 
4  Specify the number of relapses since the date of the last report:    

 
  

gfedcb
number unknown

 
 

5  Did the recipient experience continuous progression of MS since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

6  Was a MRI scan of the brain performed since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  
 
7  Date of most recent MRI: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date unknown

 
 

8  Was disease relapse / progression detected on the MRI findings?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify which MRI findings indicated disease relapse / progression: 
 

9  New gadolinium-enhancing lesions

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

10  Enlarging T2 lesions

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Key Fields 

Multiple Sclerosis Post-HSCT Data Questions: 1 - 58

Form 2143 R3.0: Multiple Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2143 revision 3.0 last updated July 2011
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 4



 
 

11  Radiology report states worsening of MS associated findings

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

12  Were the Kurtzke Functional Systems Scores (FSS) assessed by a neurologist since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  
 
13  Pyramidal score:    

 
  

gfedcb
score unknown

  
 
14  Cerebellar score:    

 
  

gfedcb
score unknown

  
 
15  Brainstem score:    

 
  

gfedcb
score unknown

  
 
16  Sensory score:    

 
  

gfedcb
score unknown

  
 
17  Bowel and bladder score:    

 
  

gfedcb
score unknown

  
 
18  Visual score:    

 
  

gfedcb
score unknown

  
 
19  Cerebral score:    

 
  

gfedcb
score unknown

  
 
20  Other function score:    

 
  

gfedcb
score unknown

 
 
21  Specify other function:    

  
 
22  Specify the Kurtzke Expanded Disability Status Scale (EDSS):    

 
  

gfedcb
EDSS unknown

  
 
23  Specify date of EDSS assessment: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date unknown

 

Post-HSCT Treatment for Multiple Sclerosis 
 

24  Did the recipient receive any treatment for MS since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the reason(s) for initiating post-HSCT therapy: 
 

25  Continued therapy from pre-HSCT

    
 nmlkji

yes  
 nmlkji

no  

 
 

26  Planned therapy per protocol

    
 nmlkji

yes  
 nmlkji

no  

 
 

27  Disease relapse

    
 nmlkji

yes  
 nmlkji

no  

 
 

28  Disease progression

    
 nmlkji

yes  
 nmlkji

no  

 
 

29  Other reason

    
 nmlkji

yes  
 nmlkji

no  

 
 
30  Specify other reason for initiating therapy:    

 
 
31  What was the date the first therapy started? __ __ __ __ - __ __- __ __  

 

Indicate all treatments for MS that the recipient received since the date of the last report: 
 

32  Alemtuzumab (Campath)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

33  Azathioprine (Azasan, Imuran)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

34  Belimumab (LymphoStat-B)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Form 2143 R3.0: Multiple Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2143 revision 3.0 last updated July 2011
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 4



 
 

35  Cladribine (2-CdA, Leustatin)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

36  Corticosteroids (chronic use, not to treat acute relapse)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

37  Corticosteroids (to treat acute relapse)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

38  Cyclophosphamide (CTX, Cytoxan, Neosar)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

39  Daclizumab (Zenapax, anti-CD25)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

40  Fingolimod (FTY720)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

41  Fumarate (oral) (BG00012)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

42  Glatiramer acetate (Copaxone) [previously copolymer-1]

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

43  Immune globulin (IVIG, Gamimune, Gammagard)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

44  Interferon beta-1a (Avonex, Rebif)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

45  Interferon beta-1b (Betaseron)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

46  Laquinimod

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

47  Methotrexate (MTX, Folex)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

48  Mitoxantrone (Novantrone)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

49  Mycophenolate mofetil (MMF, Cellcept)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

50  Natalizumab (Tysabri, Antegren)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

51  Rituximab (anti-CD20, Rituxan, MabThera)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

52  Sirolimus (Rapamune)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

53  Tacrolimus (FK 506, Prograf)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Form 2143 R3.0: Multiple Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2143 revision 3.0 last updated July 2011
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 4



 
 

54  Teriflunomide (oral) (HMR1726)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

55  Blinded randomized trial agent

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
56  Specify trial agent:    

 
 

57  Other treatment

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
58  Specify other treatment:    

 
 

  
gfedcb

If the person completing this form is a Neurologist, check here and continue with the signature lines below.

  
 
First Name:    

 
Last Name:    

  
 
Phone number:    

 
Fax number:    

 
 
E-mail address:    

Form 2143 R3.0: Multiple Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2143 revision 3.0 last updated July 2011
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 4